Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-21 pm EDT 5-day change 1st Jan Change
24.38 USD -2.52% Intraday chart for Myriad Genetics, Inc. -3.86% +27.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue MT
Eurobio Scientific: agreement with Myriad Genetics CF
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05 MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M MT
Myriad Genetics to Seek Acquisitions CI
Transcript : Myriad Genetics, Inc., Q1 2024 Earnings Call, May 07, 2024
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million. CI
Myriad Genetics Gets US Patent for SneakPeek Snap Device MT
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024 CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024 CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health MT
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics. CI
Myriad Genetics Names George Daneker Jr. as President, Chief Clinical Officer of Oncology MT
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024 CI
Chart Myriad Genetics, Inc.
More charts
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.38 USD
Average target price
25.09 USD
Spread / Average Target
+2.92%
Consensus
  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. News Myriad Genetics, Inc.
  5. Myriad Genetics Gets US Patent for SneakPeek Snap Device
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW